CMAJ: Uneven accessibility to biomarker test for lung cancer.

Interesting adoption case study in Canada. EGFR testing is not paid for by the public healthcare system in all provinces (as an aside, I had no idea that there was province-to-province variability in coverage in Canada). AstraZeneca provided financial support for testing for 12 months, and 5 labs across Canada were included in the program, utilizing a validated PCR assay for EGFR mutations. Testing rates increased significantly during the 12 months when financial support was provided (along with gefitinib prescription rates), and they decreased significantly once it was withdrawn.